FDA approves sotorasib with panitumumab for colorectal cancer
On Jan. 15, 2025, the FDA approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for KRAS G12C-mutated metastatic colorectal cancer.
Related Articles
Dr Naqash on Combining Abequolixron Plus Docetaxel in Recurrent NSCLC
Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.
9 States Poised To End Coverage for Millions if Trump Cuts Medicaid Funding – KFF Health News
About 3.7 million people are at immediate risk of losing health coverage should the federal government cut funding for Medicaid expansions, as some allies of…
Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis
Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (Calquence) for Mantle Cell Lymphoma
Latest News The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib (CALQUENCE) for Mantle Cell Lymphoma January 16, 2025 – On January 16,
Aspiring Professional Musician Finds Success in Moffitt’s Arts in Medicine Program
Corbin Smith is one of five artists-in-residence at the cancer center
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for treatment of patients…
Welcome! You are invited to join a webinar: AHNS Virtual Education Series: From the Bench to the Bedside: Using Preclinical Models to Advance the Management of Head and Neck Cancer. After registering, you will receive a confirmation email about joining the webinar.
January 22, 2025 Learning Objectives: Define the spectrum of contemporary preclinical models of HNSCC. Describe the strengths and weaknesses of contemporary preclinical models of HNSCC.…
Ciltacabtagene Autoleucel Demonstrates Efficacy for Patients With R/R Multiple Myeloma in Real-World Population
Treatment with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma demonstrated feasibility and efficacy in a real-world setting, according to recent study results.
